We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
Read MoreHide Full Article
Key Takeaways
Veeva's Study Builder Agent configures studies from protocols using existing standards and CDISC USDM.
The AI agent automates EDC forms, study visits, edit checks, testing and DQS listings.
Veeva plans early adopter availability in December 2026 with no additional EDC license.
Veeva Systems (VEEV - Free Report) recently introduced Veeva Study Builder Agent, a new AI-powered solution designed to accelerate clinical study configuration within its Clinical Data platform. The launch reinforces Veeva's push to embed AI across its life sciences software suite while helping customers streamline study setup using standardized workflows.
The announcement strengthens Veeva's broader strategy of deepening the value of its Clinical Data ecosystem rather than launching a standalone paid product. By making the agent part of its electronic data capture (EDC) offering with no additional license, Veeva aims to drive adoption, improve customer efficiency and further differentiate its platform. This could support long-term customer retention and reinforce its competitive position in the clinical trial technology market.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 23.1% compared with the industry’s 14.5% growth. However, the S&P 500 has risen 12% in the same timeframe.
The launch of Study Builder Agent is likely to strengthen Veeva's long-term growth by making its Clinical Data platform more valuable and harder for customers to replace. By enabling sponsors to configure studies much faster using their existing standards and the CDISC Unified Study Definitions Model (USDM), the AI agent can reduce manual effort, improve consistency and shorten study startup timelines.
Study Builder Agent is embedded within Veeva EDC and Data Quality System (DQS) rather than offered as a separate product. It is positioned to drive broader platform adoption, reinforce customer retention and expand the strategic importance of Veeva's connected clinical ecosystem, supporting durable revenue growth over time.
VEEV currently has a market capitalization of $43.84 billion.
Image Source: Zacks Investment Research
More on the News
Veeva's newly launched Study Builder Agent extends the company's push to embed AI into clinical trial operations by enabling sponsors to configure studies directly from a study protocol. The AI agent leverages an organization's existing standards together with the CDISC USDM, allowing study builds to become faster, more consistent and more deterministic while reducing reliance on manual configuration.
The solution automatically configures key study components, including EDC forms, study visits and edit check rules, while also generating CQL-based listings for Veeva's DQS. Beyond study setup, the agent automates testing and generates test data, helping organizations validate builds more efficiently and produce audit-ready outputs with minimal deviation from established standards.
Veeva plans to make Study Builder Agent available to early adopters in December 2026 as a built-in capability within Veeva EDC, requiring no additional license. Delivered as a Claude Cowork plugin through a Veeva-managed GitHub repository, the launch reflects the company's strategy of embedding AI into existing workflows rather than introducing a separate standalone product.
A Closer Look at Veeva EDC and DQS
Veeva EDC
Veeva EDC is the company's electronic data capture platform designed to collect, manage and validate clinical trial data across the study lifecycle. The platform enables sponsors and contract research organizations to build electronic case report forms, manage patient visits and apply edit checks that improve data accuracy during trials. Study Builder Agent enhances this workflow by automatically configuring these core study elements from a protocol, allowing customers to accelerate study startup while maintaining consistency with existing organizational standards and industry frameworks such as CDISC USDM.
Veeva DQS
Veeva DQS complements EDC by helping clinical teams identify, review and resolve data quality issues throughout a trial. The platform uses CQL-based listings and automated quality checks to detect inconsistencies, enabling sponsors to review cleaner and more reliable data before regulatory submissions. Study Builder Agent now automates the creation of these DQS listings alongside testing and test-data generation, strengthening Veeva's connected Clinical Data ecosystem by reducing manual work and supporting faster, audit-ready study builds
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva expanded its AI strategy with the launch of Falcon Router, a new agentic solution designed to help biopharma companies streamline the intake and routing of safety, quality and medical cases across reporting channels. The offering, scheduled for early adopter availability in January 2027, adds to Veeva's growing Falcon Agent Suite aimed at automating industry-specific workflows.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
Key Takeaways
Veeva Systems (VEEV - Free Report) recently introduced Veeva Study Builder Agent, a new AI-powered solution designed to accelerate clinical study configuration within its Clinical Data platform. The launch reinforces Veeva's push to embed AI across its life sciences software suite while helping customers streamline study setup using standardized workflows.
The announcement strengthens Veeva's broader strategy of deepening the value of its Clinical Data ecosystem rather than launching a standalone paid product. By making the agent part of its electronic data capture (EDC) offering with no additional license, Veeva aims to drive adoption, improve customer efficiency and further differentiate its platform. This could support long-term customer retention and reinforce its competitive position in the clinical trial technology market.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 23.1% compared with the industry’s 14.5% growth. However, the S&P 500 has risen 12% in the same timeframe.
The launch of Study Builder Agent is likely to strengthen Veeva's long-term growth by making its Clinical Data platform more valuable and harder for customers to replace. By enabling sponsors to configure studies much faster using their existing standards and the CDISC Unified Study Definitions Model (USDM), the AI agent can reduce manual effort, improve consistency and shorten study startup timelines.
Study Builder Agent is embedded within Veeva EDC and Data Quality System (DQS) rather than offered as a separate product. It is positioned to drive broader platform adoption, reinforce customer retention and expand the strategic importance of Veeva's connected clinical ecosystem, supporting durable revenue growth over time.
VEEV currently has a market capitalization of $43.84 billion.
Image Source: Zacks Investment Research
More on the News
Veeva's newly launched Study Builder Agent extends the company's push to embed AI into clinical trial operations by enabling sponsors to configure studies directly from a study protocol. The AI agent leverages an organization's existing standards together with the CDISC USDM, allowing study builds to become faster, more consistent and more deterministic while reducing reliance on manual configuration.
The solution automatically configures key study components, including EDC forms, study visits and edit check rules, while also generating CQL-based listings for Veeva's DQS. Beyond study setup, the agent automates testing and generates test data, helping organizations validate builds more efficiently and produce audit-ready outputs with minimal deviation from established standards.
Veeva plans to make Study Builder Agent available to early adopters in December 2026 as a built-in capability within Veeva EDC, requiring no additional license. Delivered as a Claude Cowork plugin through a Veeva-managed GitHub repository, the launch reflects the company's strategy of embedding AI into existing workflows rather than introducing a separate standalone product.
A Closer Look at Veeva EDC and DQS
Veeva EDC
Veeva EDC is the company's electronic data capture platform designed to collect, manage and validate clinical trial data across the study lifecycle. The platform enables sponsors and contract research organizations to build electronic case report forms, manage patient visits and apply edit checks that improve data accuracy during trials. Study Builder Agent enhances this workflow by automatically configuring these core study elements from a protocol, allowing customers to accelerate study startup while maintaining consistency with existing organizational standards and industry frameworks such as CDISC USDM.
Veeva DQS
Veeva DQS complements EDC by helping clinical teams identify, review and resolve data quality issues throughout a trial. The platform uses CQL-based listings and automated quality checks to detect inconsistencies, enabling sponsors to review cleaner and more reliable data before regulatory submissions. Study Builder Agent now automates the creation of these DQS listings alongside testing and test-data generation, strengthening Veeva's connected Clinical Data ecosystem by reducing manual work and supporting faster, audit-ready study builds
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva expanded its AI strategy with the launch of Falcon Router, a new agentic solution designed to help biopharma companies streamline the intake and routing of safety, quality and medical cases across reporting channels. The offering, scheduled for early adopter availability in January 2027, adds to Veeva's growing Falcon Agent Suite aimed at automating industry-specific workflows.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.